4576.T
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.
Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.
The company has a strong liquidity position, with cash and equivalents amounting to ¥170,979,000,000, significantly exceeding its total liabilities of ¥73,401,200,000. The current ratio of 9.91 indicates a robust ability to meet short-term obligations. However, the company is currently unprofitable, with a net loss of ¥632,086,000 and an operating loss of ¥619,870,000. The return on equity (ROE) is -0.4403, and the return on assets (ROA) is -0.2914, both significantly below industry norms.
The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.42, suggesting a low reliance on debt financing. The price-to-book ratio of 3.02 and the price-to-tangible-book ratio of 3.02 indicate that the market is valuing the company's intangible assets at a premium. Despite this, the company's negative operating and free cash flows suggest ongoing financial strain, with operating cash flow at -¥493,795,000 and free cash flow at -¥587,312,000.
The company's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no specific geographic breakdown provided. This lack of diversification could pose a risk if the company's primary market experiences a downturn. The company's growth trajectory is currently negative, with a net loss and declining profitability. Analysts have reported a last actual EPS of -13.19 JPY and a last actual revenue of ¥387,620,000, indicating a challenging operating environment.
The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. However, the negative operating and free cash flows suggest potential future liquidity constraints if the company's financial performance does not improve. The company has not issued any recent events or filings that would indicate significant changes in its operational or financial status.
- The company has a strong liquidity position with a current ratio of 9.91.
- The company is currently unprofitable with a net loss of ¥632,086,000.
- The company's capital structure is conservative with a debt-to-equity ratio of 0.42.
- The company's revenue is concentrated in a single business segment.
- The company's growth trajectory is negative with declining profitability.
- The company has low liquidity and dilution risks.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 4576.T Market data — financials · 2026-05-26
- D.Western Therapeutics Institute Inc Market data — analyst estimates · 2026-05-26